发布求助
文献互助 智能选刊 最新文献

Trends in cancer最新文献

筛选
英文 中文
Selective autophagy receptor hinders antitumor immunity. 选择性自噬受体阻碍抗肿瘤免疫。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-01-01 Epub Date: 2024-12-02 DOI: 10.1016/j.trecan.2024.11.004
Jiao Liu, Rui Kang, Daolin Tang
{"title":"Selective autophagy receptor hinders antitumor immunity.","authors":"Jiao Liu, Rui Kang, Daolin Tang","doi":"10.1016/j.trecan.2024.11.004","DOIUrl":"10.1016/j.trecan.2024.11.004","url":null,"abstract":"<p><p>Autophagy has a dual role in tumor progression and therapy, influenced by specific receptors and cargo selection. Recent research published in Cell by Herhaus et al. identifies immunity-related GTPase Q (IRGQ) as a novel autophagy receptor that facilitates immune evasion in hepatocellular carcinoma (HCC) by degrading histocompatibility complex class I (MHC-I) molecules, highlighting a potential target to enhance immunotherapy.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"4-5"},"PeriodicalIF":14.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142772652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aberrant nuclei with amplified DNA in cancer. 癌症中DNA扩增的异常细胞核。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-01-01 Epub Date: 2024-10-06 DOI: 10.1016/j.trecan.2024.09.005
Venkata Narasimha Kadali, Ofer Shoshani
{"title":"Aberrant nuclei with amplified DNA in cancer.","authors":"Venkata Narasimha Kadali, Ofer Shoshani","doi":"10.1016/j.trecan.2024.09.005","DOIUrl":"10.1016/j.trecan.2024.09.005","url":null,"abstract":"<p><p>Gene amplification in the form of extrachromosomal DNA (ecDNA) or intrachromosomal homogenous staining regions (HSRs) is an emerging hallmark in cancer. Recent studies implicate abnormal nuclear structures in the biogenesis and evolution of amplified DNA. Here, we discuss how the interplay between aberrant nuclei and gene amplification drives cancer therapy resistance and metastasis.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"9-11"},"PeriodicalIF":14.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142381736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cancer researchers as storytellers for the lay public. 癌症研究人员为普通公众讲故事。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-01-01 Epub Date: 2024-09-27 DOI: 10.1016/j.trecan.2024.09.004
William G Nelson
{"title":"Cancer researchers as storytellers for the lay public.","authors":"William G Nelson","doi":"10.1016/j.trecan.2024.09.004","DOIUrl":"10.1016/j.trecan.2024.09.004","url":null,"abstract":"<p><p>Cancer researchers tend to be well-versed in communicating research and research results to scientific audiences. To maintain momentum and progress against cancer, they must acquire and nurture skills allowing for better engagement with the lay public.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"6-8"},"PeriodicalIF":14.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142354697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nonrepair functions of DNA mismatch repair proteins: new avenues for precision oncology. DNA 错配修复蛋白的非修复功能：精准肿瘤学的新途径。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-01-01 Epub Date: 2024-10-28 DOI: 10.1016/j.trecan.2024.10.001
Jerry Tyler DeWitt, Megha Raghunathan, Svasti Haricharan
{"title":"Nonrepair functions of DNA mismatch repair proteins: new avenues for precision oncology.","authors":"Jerry Tyler DeWitt, Megha Raghunathan, Svasti Haricharan","doi":"10.1016/j.trecan.2024.10.001","DOIUrl":"10.1016/j.trecan.2024.10.001","url":null,"abstract":"<p><p>DNA damage repair (DDR) proteins are well recognized as guardians of the genome that are frequently lost during malignant transformation of normal cells across cancer types. To date, their tumor suppressor functions have been generally regarded as a consequence of their roles in maintaining genomic stability: more genomic instability increases the risk of oncogenic transformation events. However, recent discoveries centering around DNA mismatch repair (MMR) proteins suggest a broader impact of the loss of DDR proteins on cellular processes beyond genomic instability. Here, we explore the clinical implications of nonrepair roles for DDR proteins, using the growing evidence supporting roles for DNA MMR proteins in cell cycle and apoptosis regulation, metabolic function, the cellular secretome, and immunomodulation.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"49-61"},"PeriodicalIF":14.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12077842/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Generation of tumor neoantigens by RNA splicing perturbation. 通过 RNA 剪接扰乱生成肿瘤新抗原。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-01-01 Epub Date: 2024-11-22 DOI: 10.1016/j.trecan.2024.10.008
Adi Rosenberg-Mogilevsky, Zahava Siegfried, Rotem Karni
{"title":"Generation of tumor neoantigens by RNA splicing perturbation.","authors":"Adi Rosenberg-Mogilevsky, Zahava Siegfried, Rotem Karni","doi":"10.1016/j.trecan.2024.10.008","DOIUrl":"10.1016/j.trecan.2024.10.008","url":null,"abstract":"<p><p>Immunotherapy has revolutionized cancer treatment, but the limited availability of tumor-specific neoantigens still remains a challenge. The potential of alternative mRNA splicing-derived neoantigens as a source of new immunotherapy targets has gained significant attention. Tumors exhibit unique splicing changes and splicing factor mutations which are prevalent in various cancers and play a crucial role in neoantigen production. We present advances in splicing modulation approaches, including small-molecule drugs, decoy and splice-switching antisense oligonucleotides (SSOs), CRISPR, small interfering RNAs (siRNAs), and nonsense-mediated RNA decay (NMD) inhibition, that can be adapted to enhance antitumor immune responses. Finally, we explore the clinical implications of these approaches, highlighting their potential to transform cancer immunotherapy and broaden its efficacy.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"12-24"},"PeriodicalIF":14.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142693709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exercise against nonsmall-cell lung carcinoma: novel insights. 运动对抗非小细胞肺癌：新见解。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-01-01 Epub Date: 2024-12-04 DOI: 10.1016/j.trecan.2024.11.006
Abel Plaza-Florido, Carmen Fiuza-Luces, Alejandro Lucia
{"title":"Exercise against nonsmall-cell lung carcinoma: novel insights.","authors":"Abel Plaza-Florido, Carmen Fiuza-Luces, Alejandro Lucia","doi":"10.1016/j.trecan.2024.11.006","DOIUrl":"10.1016/j.trecan.2024.11.006","url":null,"abstract":"<p><p>The mechanisms underlying the potential 'anticancer' effects of exercise remain poorly understood. Luo et al. recently identified an exercise-induced, muscle-derived extracellular vesicle (EV)-associated miR, miR-29a-3p, as a key player in the potential benefits of exercise against nonsmall-cell lung carcinoma (NSCLC), including extracellular matrix (ECM) inhibition and improved antitumoral immune responses.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"1-3"},"PeriodicalIF":14.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142787132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neoadjuvant combination immunotherapy in MSI/dMMR colorectal cancer. MSI/dMMR 大肠癌的新辅助联合免疫疗法。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2024-12-01 Epub Date: 2024-10-24 DOI: 10.1016/j.trecan.2024.10.006
Meggy Suarez-Carmona, Niels Halama
{"title":"Neoadjuvant combination immunotherapy in MSI/dMMR colorectal cancer.","authors":"Meggy Suarez-Carmona, Niels Halama","doi":"10.1016/j.trecan.2024.10.006","DOIUrl":"10.1016/j.trecan.2024.10.006","url":null,"abstract":"<p><p>Neoadjuvant immune checkpoint inhibition (ICI) is a new approach to treat patients with colorectal cancer (CRC). The effects of combined neoadjuvant ICI in locally advanced, DNA mismatch repair (dMMR)-deficient/microsatellite instable (MSI) CRC were recently reported by de Gooyer et al. from the NICHE-3 trial. Further studies will determine whether these impressive pathological responses lead to long-term clinical benefit.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"1093-1094"},"PeriodicalIF":14.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142508858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
EZHIP's role in diffuse midline glioma: echoes of oncohistones? EZHIP 在弥漫性中线胶质瘤中的作用：与癌基因的呼应？
IF 14.3 1区 医学
Trends in cancer Pub Date : 2024-12-01 Epub Date: 2024-09-28 DOI: 10.1016/j.trecan.2024.09.002
Afraah Cassim, Matthew D Dun, David Gallego-Ortega, Fatima Valdes-Mora
{"title":"EZHIP's role in diffuse midline glioma: echoes of oncohistones?","authors":"Afraah Cassim, Matthew D Dun, David Gallego-Ortega, Fatima Valdes-Mora","doi":"10.1016/j.trecan.2024.09.002","DOIUrl":"10.1016/j.trecan.2024.09.002","url":null,"abstract":"<p><p>The enhancer of zeste inhibitory protein (EZHIP) is typically expressed during germ cell development and has been classified as a cancer-testis antigen (CTA) in various cancers. In 2020, 4% of diffuse midline gliomas (DMGs) were shown to aberrantly express EZHIP, mirroring the DMG hallmark histone H3 K27M (H3K27M) oncohistone mutation. Similar to H3K27M, EZHIP is a negative regulator of polycomb repressive complex 2 (PRC2), leading to global epigenomic remodeling. In this opinion, we explore the similarities and disparities between H3K27M- and EZHIP-DMGs with a focus on their shared functional hallmark of PRC2 inhibition, their genetic and epigenomic landscapes, plausible differences in the cell of origin, and therapeutic avenues. Upcoming research on EZHIP will help better understand its role in gliomagenesis and DMG therapy.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"1095-1105"},"PeriodicalIF":14.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142354699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Malignant glioma remodeling of neuronal circuits: therapeutic opportunities and repurposing of antiepileptic drugs. 恶性胶质瘤重塑神经元回路：治疗机会和抗癫痫药物的再利用。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2024-12-01 Epub Date: 2024-09-25 DOI: 10.1016/j.trecan.2024.09.003
Cesar Nava Gonzales, Mikias B Negussie, Saritha Krishna, Vardhaan S Ambati, Shawn L Hervey-Jumper
{"title":"Malignant glioma remodeling of neuronal circuits: therapeutic opportunities and repurposing of antiepileptic drugs.","authors":"Cesar Nava Gonzales, Mikias B Negussie, Saritha Krishna, Vardhaan S Ambati, Shawn L Hervey-Jumper","doi":"10.1016/j.trecan.2024.09.003","DOIUrl":"10.1016/j.trecan.2024.09.003","url":null,"abstract":"<p><p>Tumor-associated epilepsy is the most common presenting symptom in patients diagnosed with diffuse gliomas. Recent evidence illustrates the requirement of synaptic activity to drive glioma proliferation and invasion. Class 1, 2, and 3 evidence is limited regarding the use of antiepileptic drugs (AEDs) as antitumor therapy in combination with chemotherapy. Furthermore, no central mechanism has emerged as the most targetable. The optimal timing of AED regimen remains unknown. Targeting aberrant neuronal activity is a promising avenue for glioma treatment. Clinical biomarkers may aid in identifying patients most likely to benefit from AEDs. Quality evidence is needed to guide treatment decisions.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"1106-1115"},"PeriodicalIF":14.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142354700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The UPRising connection between endoplasmic reticulum stress and the tumor microenvironment. 内质网应激与肿瘤微环境之间的联系日益突出。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2024-12-01 Epub Date: 2024-10-29 DOI: 10.1016/j.trecan.2024.09.011
Hery Urra, Raúl Aravena, Lucas González-Johnson, Claudio Hetz
{"title":"The UPRising connection between endoplasmic reticulum stress and the tumor microenvironment.","authors":"Hery Urra, Raúl Aravena, Lucas González-Johnson, Claudio Hetz","doi":"10.1016/j.trecan.2024.09.011","DOIUrl":"10.1016/j.trecan.2024.09.011","url":null,"abstract":"<p><p>The tumor microenvironment (TME) represents a dynamic network of cancer cells, stromal cells, immune mediators, and extracellular matrix components, crucial for cancer progression. Stress conditions such as oncogene activation, nutrient deprivation, and hypoxia disrupt the endoplasmic reticulum (ER), activating the unfolded protein response (UPR), the main adaptive mechanism to restore ER function. The UPR regulates cancer progression by engaging cell-autonomous and cell-non-autonomous mechanisms, reprogramming the stroma and promoting immune evasion, angiogenesis, and invasion. This review explores the role of UPR beyond cancer cells, focusing on how ER stress signaling reshapes the TME, supporting tumor growth. The therapeutic potential of targeting the UPR is also discussed.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"1161-1173"},"PeriodicalIF":14.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142547714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信